Find Clinical Trial
An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Cancers |
| Indication | Refractory metastatic colorectal cancer, Solid tumors |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S.) |
| Active substance/ Medical device |
TIPIRACIL, TRIFLURIDINE, |
| Active Substance Code | S095005 |
| Protocol Code | CL3-95005-007 |
| EudraCT Code | 2020-001976-14 |
| NCT Code | NCT04737187 |
Documents and links
| First lay summary | |
| Second lay summary | |
| First results summary | READ MORE  |
| Second results summary | READ MORE |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
